{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:06:35Z","timestamp":1783901195520,"version":"3.55.0"},"reference-count":20,"publisher":"Walter de Gruyter GmbH","issue":"1","license":[{"start":{"date-parts":[[2020,1,21]],"date-time":"2020-01-21T00:00:00Z","timestamp":1579564800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,1,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_raon-2020-0002_s_006_w2aab3b8c51b1b7b1aab1c16b1Aa\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      The aim of the study was to evaluate the safety and feasibility of intra-arterial mitomycin C (MMC) infusion after selective internal radiation therapy (SIRT) using Yttrium-90 (\n                      <jats:sup>90<\/jats:sup>\n                      Y) resin microspheres in liver metastatic breast cancer (LMBC) patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_raon-2020-0002_s_007_w2aab3b8c51b1b7b1aab1c16b2Aa\">\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>\n                      The prospective pilot study included LMBC patients from 2012\u20132018. Patients first received infusion of\n                      <jats:sup>90<\/jats:sup>\n                      Y resin microspheres, after 6\u20138 weeks response to treatment was assessed by MRI,\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG PET\/CT and laboratory tests. After exclusion of progressive disease, MMC infusion was administrated 8 weeks later in different dose cohorts; A: 6 mg in 1 cycle, B: 12 mg in 2 cycles, C: 24 mg in 2 cycles and D: maximum of 72 mg in 6 cycles. In cohort D the response was evaluated after every 2 cycles and continued after exclusion of progressive disease. Adverse events (AE) were reported according to CTCAE version 5.0.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_raon-2020-0002_s_008_w2aab3b8c51b1b7b1aab1c16b3Aa\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Sixteen patients received\n                      <jats:sup>90<\/jats:sup>\n                      Y treatment. Four patients were excluded for MMC infusion, because of extra hepatic disease progression (n = 3) and clinical and biochemical instability (n = 1). That resulted in the following number of patient per cohort; A: 2, B: 1, C: 3 and D: 6. In 4 of the 12 patients (all cohort D) the maximum dose of MMC was adjusted due biochemical toxicities (n = 2) and progressive disease (n = 2). One grade 3 AE occurred after\n                      <jats:sup>90<\/jats:sup>\n                      Y treatment consisting of a gastrointestinal ulcer whereby prolonged hospitalization was needed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_raon-2020-0002_s_009_w2aab3b8c51b1b7b1aab1c16b4Aa\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Sequential treatment of intra-arterial infusion of MMC after\n                      <jats:sup>90<\/jats:sup>\n                      Y SIRT was feasible in 75% of the patients when MMC was administrated in different escalating dose cohorts. However, caution is needed to prevent reflux after\n                      <jats:sup>90<\/jats:sup>\n                      Y SIRT in LMBC patients.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.2478\/raon-2020-0002","type":"journal-article","created":{"date-parts":[[2020,1,22]],"date-time":"2020-01-22T04:02:42Z","timestamp":1579665762000},"page":"33-39","source":"Crossref","is-referenced-by-count":8,"title":["Sequential intra-arterial infusion of\n                    <sup>90<\/sup>\n                    Y-resin microspheres and mitomycin C in chemo refractory liver metastatic breast cancer patients: a single centre pilot study"],"prefix":"10.2478","volume":"54","author":[{"given":"Brigitte Maximiliana","family":"Aarts","sequence":"first","affiliation":[{"name":"Radiology, The Netherlands Cancer Institute , Amsterdam , The Netherlands"},{"name":"GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre , Maastricht , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth Genevi\u00e8ve","family":"Klompenhouwer","sequence":"additional","affiliation":[{"name":"Radiology, The Netherlands Cancer Institute , Amsterdam , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rapha\u00ebla Carmen","family":"Dresen","sequence":"additional","affiliation":[{"name":"Radiology, University Hospitals Leuven , Leuven , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe Michel Albert Louis Omer","family":"Deroose","sequence":"additional","affiliation":[{"name":"Nuclear Medicine, University Hospitals Leuven , Leuven , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina Gien Hoa","family":"Beets-Tan","sequence":"additional","affiliation":[{"name":"Radiology, The Netherlands Cancer Institute , Amsterdam , The Netherlands"},{"name":"GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre , Maastricht , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Punie","sequence":"additional","affiliation":[{"name":"General Medical Oncology, University Hospitals Leuven , Leuven , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Neven","sequence":"additional","affiliation":[{"name":"General Medical Oncology, University Hospitals Leuven , Leuven , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Wildiers","sequence":"additional","affiliation":[{"name":"General Medical Oncology, University Hospitals Leuven , Leuven , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geert","family":"Maleux","sequence":"additional","affiliation":[{"name":"Radiology, University Hospitals Leuven , Leuven , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2020,1,21]]},"reference":[{"key":"2026071212044610531_j_raon-2020-0002_ref_001_w2aab3b8c51b1b7b1ab2ab1Aa","doi-asserted-by":"crossref","unstructured":"Eichbaum MHR, Kaltwasser M, Bruckner T, De Rossi TM, Schneeweiss A, Sohn C. Prognostic factors for patients with liver metastases from breast cancer. Breast Cancer Res Treat 2006; 96: 53-62. doi: 10.1007\/s10549-005-9039-1","DOI":"10.1007\/s10549-005-9039-1"},{"key":"2026071212044610531_j_raon-2020-0002_ref_002_w2aab3b8c51b1b7b1ab2ab2Aa","doi-asserted-by":"crossref","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018; 68: 7-30. doi: 10.3322\/caac.21442","DOI":"10.3322\/caac.21442"},{"key":"2026071212044610531_j_raon-2020-0002_ref_003_w2aab3b8c51b1b7b1ab2ab3Aa","doi-asserted-by":"crossref","unstructured":"Ruiz A, Sebagh M, Wicherts DA, Castro-Benitez C, Van Hillegersberg R, Paule B, et al. Long-term survival and cure model following liver resection for breast cancer metastases. Breast Cancer Res and Treat 2018; 170: 89-100. doi: 10.1007\/s10549-018-4714-1","DOI":"10.1007\/s10549-018-4714-1"},{"key":"2026071212044610531_j_raon-2020-0002_ref_004_w2aab3b8c51b1b7b1ab2ab4Aa","doi-asserted-by":"crossref","unstructured":"Golse N, Adam R. Liver metastases from breast cancer: what role for surgery? Indications and results. Clin Breast Cancer 2017; 17: 256-65. doi: 10.1016\/j.clbc.2016.12.012","DOI":"10.1016\/j.clbc.2016.12.012"},{"key":"2026071212044610531_j_raon-2020-0002_ref_005_w2aab3b8c51b1b7b1ab2ab5Aa","doi-asserted-by":"crossref","unstructured":"Ghersi D, Wilcken N, Simes RJ. A systematic review of taxane-containing regimens for metastatic breast cancer. Br J Cancer 2005; 93: 293-301. doi: 10.1038\/sj.bjc.6602680","DOI":"10.1038\/sj.bjc.6602680"},{"key":"2026071212044610531_j_raon-2020-0002_ref_006_w2aab3b8c51b1b7b1ab2ab6Aa","doi-asserted-by":"crossref","unstructured":"Gordon AC, Uddin OM, Riaz A, Salem R, Lewandowski RJ. Making the case: intra-arterial therapy for less common metastases. Semin Intervent Radiol 2017; 34: 132-9. doi: 10.1055\/s-0037-1601852","DOI":"10.1055\/s-0037-1601852"},{"key":"2026071212044610531_j_raon-2020-0002_ref_007_w2aab3b8c51b1b7b1ab2ab7Aa","doi-asserted-by":"crossref","unstructured":"Smits ML, Prince JF, Rosenbaum CE, van den Hoven AF, Nijsen JF, Zonnenberg BA, et al: Intra-arterial radioembolization of breast cancer liver metastases: a structured review. Eur J Pharmacol 2013; 709: 37-42. doi: 10.1016\/j.ejphar.2012.11.067","DOI":"10.1016\/j.ejphar.2012.11.067"},{"key":"2026071212044610531_j_raon-2020-0002_ref_008_w2aab3b8c51b1b7b1ab2ab8Aa","doi-asserted-by":"crossref","unstructured":"Wang M, Zhang J, Ji S, Shao G, Zhao K, Wang Z, et al. Transarterial chemoembolisation for breast cancer with liver metastasis: a systematic review. Breast 2017; 36: 25-30. doi: 10.1016\/j.breast.2017.09.001","DOI":"10.1016\/j.breast.2017.09.001"},{"key":"2026071212044610531_j_raon-2020-0002_ref_009_w2aab3b8c51b1b7b1ab2ab9Aa","doi-asserted-by":"crossref","unstructured":"Aarts BM, Klompenhouwer EG, Dresen RC, Laenen A, Beets-Tan RGH, Punie K, et al. Intra-arterial mitomycin C infusion in a large cohort of advanced liver metastatic breast cancer patients: safety, efficacy and factors influencing survival. Breast Cancer Res Treat 2019; 176: 597-605. doi: 10.1007\/s10549-019-05254-4","DOI":"10.1007\/s10549-019-05254-4"},{"key":"2026071212044610531_j_raon-2020-0002_ref_010_w2aab3b8c51b1b7b1ab2ac10Aa","doi-asserted-by":"crossref","unstructured":"Fendler WP, Lechner H, Todica A, Paprottka KJ, Paprottka PM, Jakobs TF, et al. Safety, efficacy and prognostic factors after radioembolization of hepatic metastases from breast cancer: a large single center experience in 81 patients. J Nucl Med 2016; 57: 517-23. doi: 10.2967\/jnumed.115.165050","DOI":"10.2967\/jnumed.115.165050"},{"key":"2026071212044610531_j_raon-2020-0002_ref_011_w2aab3b8c51b1b7b1ab2ac11Aa","doi-asserted-by":"crossref","unstructured":"Pieper CC, Meyer C, Wilhelm KE, Block W, Nadal J, Ahmadzadehfar H, et al. Yttrium-90 radioembolization of advanced, unresectable breast cancer liver metastases-a single-center experience. J Vasc Interv Radiol 2016; 27: 1305-15. doi: 10.1016\/j.jvir.2016.05.028","DOI":"10.1016\/j.jvir.2016.05.028"},{"key":"2026071212044610531_j_raon-2020-0002_ref_012_w2aab3b8c51b1b7b1ab2ac12Aa","doi-asserted-by":"crossref","unstructured":"Gordon AC, Salem R, Lewandowski RJ. Yttrium-90 radioembolization for breast cancer liver metastases. J Vasc Interv Radiol 2016, 27: 1316-9. doi: 10.1016\/j.jvir.2016.06.016","DOI":"10.1016\/j.jvir.2016.06.016"},{"key":"2026071212044610531_j_raon-2020-0002_ref_013_w2aab3b8c51b1b7b1ab2ac13Aa","doi-asserted-by":"crossref","unstructured":"Maleux G, Deroose C, Laenen A, Verslype C, Heye S, Haustermans K et al. Yttrium-90 radioembolization for the treatment of chemorefractory colorectal liver metastases: technical results, clinical outcome and factors potentially influencing survival. Acta Oncologica 2016; 55: 486-95. doi: 10.3109\/0284186X.2015.1101151","DOI":"10.3109\/0284186X.2015.1101151"},{"key":"2026071212044610531_j_raon-2020-0002_ref_014_w2aab3b8c51b1b7b1ab2ac14Aa","doi-asserted-by":"crossref","unstructured":"Maes T, Wildiers H, Heye S, Demey W, Maleux G, Neven P, et al. Intrahepatic mitomycin C bolus infusion in the treatment of extensive liver metastases of breast cancer. Breast Cancer Res Treat 2008; 110: 135-42. doi:10.1007\/s10549-007-9707-4","DOI":"10.1007\/s10549-007-9707-4"},{"key":"2026071212044610531_j_raon-2020-0002_ref_015_w2aab3b8c51b1b7b1ab2ac15Aa","doi-asserted-by":"crossref","unstructured":"Tirkes T, Hollar MA, Tann M, Kohli MD, Akisik F, Sandrasegaran K. Response criteria in oncologic imaging: review of traditional and new criteria. Radiographics 2013; 33: 1323-41. doi: 10.1148\/rg.335125214","DOI":"10.1148\/rg.335125214"},{"key":"2026071212044610531_j_raon-2020-0002_ref_016_w2aab3b8c51b1b7b1ab2ac16Aa","doi-asserted-by":"crossref","unstructured":"Pieper CC, Willinek WA, Thomas D, Ahmadzadehfar H, Essler M, Nadal J, et al: Incidence and risk factors of early arterial blood flow stasis during first radioembolization of primary and secondary liver malignancy using resin microspheres: an initial single-center analysis. Eur Radiology 2016; 26: 2779-89. doi: 10.1007\/s00330-015-4076-6","DOI":"10.1007\/s00330-015-4076-6"},{"key":"2026071212044610531_j_raon-2020-0002_ref_017_w2aab3b8c51b1b7b1ab2ac17Aa","doi-asserted-by":"crossref","unstructured":"Collins J, Salem R. Hepatic radioembolization complicated by gastrointestinal ulceration. Semin Intervent Radiol 2011; 28: 240-5. doi: 10.1055\/s-0031-1280673","DOI":"10.1055\/s-0031-1280673"},{"key":"2026071212044610531_j_raon-2020-0002_ref_018_w2aab3b8c51b1b7b1ab2ac18Aa","doi-asserted-by":"crossref","unstructured":"Saxena A, Kapoor J, Meteling B, Morris DL, Bester L. Yttrium-90 radioembolization for unresectable, chemoresistant breast cancer liver metastases: a large single-center experience of 40 patients. Ann Surg Oncol 2014; 21: 1296-303. doi: 10.1245\/s10434-013-3436-1","DOI":"10.1245\/s10434-013-3436-1"},{"key":"2026071212044610531_j_raon-2020-0002_ref_019_w2aab3b8c51b1b7b1ab2ac19Aa","doi-asserted-by":"crossref","unstructured":"Bangash AK, Atassi B, Kaklamani V, Rhee TK, Yu M, Lewandowski RJ, et al. 90Y radioembolization of metastatic breast cancer to the liver: toxicity, imaging response, survival. J Vasc Interv Radiol 2007; 18: 621-8. doi: 10.1016\/j. jvir.2007.02.019","DOI":"10.1016\/j.jvir.2007.02.019"},{"key":"2026071212044610531_j_raon-2020-0002_ref_020_w2aab3b8c51b1b7b1ab2ac20Aa","doi-asserted-by":"crossref","unstructured":"Jakobs TF, Hoffmann RT, Fischer T, Stemmler HJ, Tatsch K, La Fougere C, et al. Radioembolization in patients with hepatic metastases from breast cancer. J Vasc Interv Radiol 2008; 19: 683-90. doi: 10.1016\/j.jvir.2008.01.009","DOI":"10.1016\/j.jvir.2008.01.009"}],"container-title":["Radiology and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/content.sciendo.com\/view\/journals\/raon\/54\/1\/article-p33.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/reference-global.com\/pdf\/10.2478\/raon-2020-0002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T23:09:35Z","timestamp":1783897775000},"score":1,"resource":{"primary":{"URL":"https:\/\/reference-global.com\/article\/10.2478\/raon-2020-0002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,21]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,1,21]]},"published-print":{"date-parts":[[2020,1,21]]}},"alternative-id":["10.2478\/raon-2020-0002"],"URL":"https:\/\/doi.org\/10.2478\/raon-2020-0002","relation":{},"ISSN":["1581-3207"],"issn-type":[{"value":"1581-3207","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,21]]}}}